Biologic Specimen and Data Repository Information Coordinating Center
Home > Proprietary Studies > TOPCAT

Resources Available

Specimens Only

Materials Available

Packed Cells
Whole Blood

Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT)

Parent Study Contact: Akshay Desai,
Study Type: Clinical Trial
Prepared on August 4, 2011
Consent: Restricted Consent
Consent Restrictions: For protocol use only
Commercial Use Restrictions: No
Collection Type: Proprietary Study - See bottom of this webpage for request information


TOPCAT is a multi-center, international, randomized, double blind placebo-controlled trial of the aldosterone antagonist spironolactone, in 3515 adults with heart failure and left ventricular ejection fraction of at least 45%, recruited from over 200 clinical centers. The primary endpoint is a composite of cardiovascular mortality, aborted cardiac arrest or hospitalization for the management of heart failure. Secondary endpoints include all-cause mortality, new onset of diabetes mellitus or atrial fibrillation, and quality of life.